Frédéric Di Fiore
Frédéric Di Fiore is an expert in Oncology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Frédéric Di Fiore in the top 1% of experts worldwide for Carcinoma, Gastrointestinal Neoplasms and Intestinal Neoplasms. Frédéric Di Fiore has authored 243 publications, the most recent in 2026, and is an investigator in 51 clinical trials, 23 of them ongoing. SLR score: 1,229 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gastroenterology - Immunology - Hepatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 243
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Mucosal tissue cues shape B cell memory through the IgA BCR. PMID 42467745 — cells, immunoglobulin a, tissues, mucous membrane, memory, b-lymphocytes, infections, memory b cells | Sci Immunol | 2026 | 1 |
| Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT database. PMID 42466102 — neoplasms, adenocarcinoma, drug therapy, chemotherapy | Ther Adv Med Oncol | 2026 | 0 |
| Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. PMID 42330996 — liver diseases, hypertension, carcinoma, hepatocellular, bevacizumab, transaminases, drug-related side effects and adverse reactions, therapeutics, ipilimumab, gastrointestinal diseases | Lancet Gastroenterol Hepatol Top journal | 2026 | 5 |
| Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study. PMID 42387196 — single photon emission computed tomography computed tomography, neoplasms, prostate, positron emission tomography computed tomography, neoplasm metastasis, tomography, emission-computed, single-photon, prostatic neoplasms, therapeutics | EJNMMI Res | 2026 | 1 |
| Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol. PMID 42379715 — neoplasms, cohort studies, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, dna, prognosis, chemotherapy | BMJ Open | 2026 | 0 |
Clinical Studies 51
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
23 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma 2025-522395-92-00 — trifluridine, adenocarcinoma | Phase 3 | Recruiting | 2025 |
| A clinical study of MK 1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK 1084 012) 2024-517232-22-00 — safety, cetuximab, neoplasms, bevacizumab, drug therapy, therapeutics, colorectal neoplasms, chemotherapy | Phase 3 | Recruiting | 2025 |
| Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated Unresectable or Metastatic Colorectal Cancer 2025-523224-45-00 — pharmaceutical preparations, neoplasms, bevacizumab, drug therapy, colorectal neoplasms, chemotherapy | Phase 2/Phase 3 | Not yet recruiting | 2026 |
| ENGIC 01 COLOSOTO A single arm phase II study evaluating 5 fluorouracil plus Panitumumab (anti EGFR) and Sotorasib (KRAS G12C inhibitor) in first line treatment of patients non eligible for a doublet triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma 2024-514030-20-00 — neoplasms, adenocarcinoma, drug therapy, fluorouracil, panitumumab, therapeutics, colorectal neoplasms, chemotherapy | Phase 2 | Recruiting | 2025 |
| PRODIGE 88 CIRCULATE PAC Phase III multicentric open label randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high risk stage II and stage III Colorectal Cancer 2023-505046-26-00 — neoplasms, colon, drug therapy, chemotherapy, adjuvant, colorectal neoplasms, chemotherapy, carcinoma | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map